Combined Treatment with Hyaluronic Acid and Mesalamine Protects Rats from Inflammatory Bowel Disease Induced by Intracolonic Administration of Trinitrobenzenesulfonic Acid

• Published in: Molecules (Basel, Switzerland) Vol. 22; no. 6; p. 904
• Main Authors: Chiu, Chih-Tung, Kuo, Sheng-Nan, Hung, Shao-Wen, Yang, Cheng-Yao
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.05.2017; MDPI
• Subjects: Animals; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; colitis; Colon; Cyclooxygenase 2 - metabolism; Cytokines - metabolism; Disease Models, Animal; hyaluronic acid; Hyaluronic Acid - pharmacology; Inflammation Mediators - metabolism; Inflammatory bowel disease; Inflammatory Bowel Diseases - chemically induced; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - metabolism; Inflammatory Bowel Diseases - pathology; Intestinal Mucosa - drug effects; Intestinal Mucosa - metabolism; Intestinal Mucosa - pathology; Male; Mesalamine - pharmacology; mucosal healing; Peroxidase - metabolism; Protective Agents - pharmacology; Rats; remission; Rodents; Trinitrobenzenesulfonic Acid - administration & dosage; Trinitrobenzenesulfonic Acid - adverse effects; Wound healing; colitis; inflammatory bowel disease; remission; hyaluronic acid; mucosal healing
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules22060904

Drugs such as mesalamine (5-ASA) are currently recommended for the treatment of inflammatory bowel disease (IBD). To reduce the frequency of their administration and improve their therapeutic effect, this study investigated the adhesion efficacy, wound healing promotion, and decrease in inflammation in ulcers in the colonic tissue of rats with colitis after combined treatment with hyaluronic acid (HA) and 5-ASA (IBD98-M). HA-fluoresceinamine (FL) conjugates successfully adhered to the mucosal layer and were conjugated in the vascular tissue. In addition, macroscopic and microscopic observations indicated that colonic injuries reduced significantly after treatment with IBD98-M. Compared with PBS and 5-ASA treatment alone, treatment with IBD98-M more effectively reduced bowel inflammation and promoted colonic mucosal healing in TNBS-induced colitis. IBD98-M treatment also reduced myeloperoxidase activity and the expression levels of cyclooxygenase 2 and tumor necrosis factor-αin the colitis tissue. In conclusion, IBD98-M treatment strongly promoted wound healing in colonic injuries and significantly inhibited MPO activity in the inflamed colon tissue of rats. Combined treatment with HA and 5-ASA can accelerate wound healing and reduce inflammatory reaction in rat colitis.